Literature DB >> 3459563

Clotting complications of L-asparaginase therapy in children with ALL.

M G Cappellato, A Rosolen, L Zanesco, A Girolami.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3459563     DOI： 10.1007/BF00320785

Source DB:  PubMed          Journal:  Blut        ISSN： 0006-5242


× No keyword cloud information.
  6 in total

1.  The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia.

Authors:  N K Ramsay; P F Coccia; W Krivit; M E Nesbit; J R Edson
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

2.  Hypofibrinogenemia due to L-asparaginase: studies of fibrinogen survival using autologous 131-I-fibrinogen.

Authors:  R E Bettigole; E S Himelstein; H F Oettgen; G O Clifford
Journal:  Blood       Date:  1970-02       Impact factor: 22.113

3.  Hypofibrinogenemia and coagulation factor deficiencies with L-asparaginase treatment.

Authors:  H R Gralnick; E Henderson
Journal:  Cancer       Date:  1971-06       Impact factor: 6.860

4.  Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase.

Authors:  H A Liebman; J K Wada; M J Patch; W McGehee
Journal:  Cancer       Date:  1982-08-01       Impact factor: 6.860

5.  A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia.

Authors:  J R Priest; N K Ramsay; P G Steinherz; D G Tubergen; M S Cairo; A L Sitarz; A J Bishop; L White; M E Trigg; C J Levitt; J A Cich; P F Coccia
Journal:  J Pediatr       Date:  1982-06       Impact factor: 4.406

6.  Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and vincristine.

Authors:  C H Pui; C W Jackson; C Chesney; S A Lyles; W P Bowman; M Abromowitch; J V Simone
Journal:  J Clin Oncol       Date:  1983-06       Impact factor: 44.544
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.